ALNY Jan 2025 175.000 put
- Bloomberg
Alnylam Soars After Drug Meets Goal in Heart Disease Trial
(Bloomberg) -- Alnylam Pharmaceuticals Inc. shares soared after its drug succeeded in treating a progressive and deadly form of heart disease, potentially opening up a new avenue for the company’s top-selling product. Most Read from BloombergHow Long Can High Rates Last? Bond Markets Say Maybe ForeverNvidia Sales Grow So Fast That Wall Street Can’t Keep UpJain Raises $5.3 Billion in Biggest Hedge Fund Debut Since 2018Russia Is Storing Up a Crime Wave When Its War on Ukraine EndsNasdaq Futures Un
- Investor's Business Daily
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
- Business Wire
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
CAMBRIDGE, Mass., June 24, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).
